Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Non Operating Income (2016 - 2025)

Cytosorbents (CTSO) has disclosed Non Operating Income for 14 consecutive years, with -$709000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non Operating Income fell 134.38% year-over-year to -$709000.0, compared with a TTM value of -$1.8 million through Sep 2025, down 166.32%, and an annual FY2024 reading of -$5.6 million, down 397.85% over the prior year.
  • Non Operating Income was -$709000.0 for Q3 2025 at Cytosorbents, down from $2.4 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $4.5 million in Q4 2022 and bottomed at -$5.5 million in Q4 2024.
  • Average Non Operating Income over 5 years is -$387179.1, with a median of -$716662.0 recorded in 2024.
  • Peak annual rise in Non Operating Income hit 1034.68% in 2022, while the deepest fall reached 1120.29% in 2022.
  • Year by year, Non Operating Income stood at -$481194.0 in 2021, then soared by 1034.68% to $4.5 million in 2022, then crashed by 38.64% to $2.8 million in 2023, then tumbled by 300.37% to -$5.5 million in 2024, then surged by 87.18% to -$709000.0 in 2025.
  • Business Quant data shows Non Operating Income for CTSO at -$709000.0 in Q3 2025, $2.4 million in Q1 2025, and -$5.5 million in Q4 2024.